Quarter
Charts

EMERGENT BIOSOLUTIONS INC.

EBS

CIK 0001367644 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$149M
↓-23.6% -$46Mvs FY2024 (Q4)
Gross Profit
$64M
↓-16.8% -$13Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
46/100
  • Profitability
    3ROIC 5.5% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 5.01 (above 1.5 = solid)
  • Leverage
    44D/E 1.13 (under 0.5 = conservative)
  • Efficiency
    27Asset Turnover 0.55x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -23.6% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin 33.1% · trend +33.8pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project EBS's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$47.57
Total enterprise IV
$2.70B
Diluted shares
0.06B
Terminal PV
$1.96B (72% of total)
Year-5 FCF
$230M
YearProjected FCFDiscounted PV
+1$169M$154M
+2$183M$151M
+3$198M$148M
+4$213M$146M
+5$230M$143M
Terminal$3.15B$1.96B

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$14M
investment in PP&E
Stock buybacks (TTM)
$25M
share count reduction
Stock-based comp (TTM)
$16M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$1.32B
everything owned
Total liabilities
$796M
everything owed
Stockholders' equity
$523M
shareholder claim
Net debt
$384M
LT debt minus cash

Recent performance · 63 quarters

Revenue↓-23.6% -$46M
$149M
Net Income↓-55.4% -$64M
$51M
Free Cash Flow↑+4441.2% +$76M
$74M
Operating Margin↑+11.1pts
33.1%

Drill down

EBS Sankey

See EMERGENT BIOSOLUTIONS INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

EBS Charts

63 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

EBS Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics